Page 89 - Read Online

Page 8 of 8 Yang et al. Hepatoma Res 2020;6:31 I http://dx.doi.org/10.20517/2394-5079.2019.45

with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology
2018;154:515-517.e3.
20. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, et al.; HCV Research UK. Outcomes after successful direct-acting
antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-7.
21. Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, et al.; Ochanomizu Liver Conference Study Group. Effect of interferon-based and
-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 2017;67:933-9.
22. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting
antiviral agents. Gastroenterology 2017;153:996-1005.e1.
23. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
J Hepatol 2017:25-32.
24. Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, et al. Direct-acting antiviral treatment for hepatitis C virus infection and risk
of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther 2018;47:1278-87.
25. Innes H, Barclay ST, Hayes PC, Fraser A, Dillon JF, et al. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and
sustained viral response: role of the treatment regimen. J Hepatol 2018;68:646-54.
26. Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, et al. The short-term incidence of hepatocellular carcinoma is not increased after
hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology 2018;67:2244-53.
27. Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, et al. Newly diagnosed hepatocellular carcinoma in patients with
advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol 2018;69:345-52.
28. Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, et al.; ANRS CO12 CirVir Group. Incidence of hepatocellular carcinoma after
direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology 2018;155:1436-50.e6.
29. Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, et al.; Rete Sicilia Selezione Terapia–HCV (RESIST-HCV). Incidence
of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology
2018;155:411-21.e4.
30. Lleo A, Aglitti A, Aghemo A, Maisonneuve P, Bruno S, et al.; collaborators. Predictors of hepatocellular carcinoma in HCV cirrhotic
patients treated with direct acting antivirals. Dig Liver Dis 2019;51:310-7.
31. Mettke F, Schlevogt B, Deterding K, Wranke A, Smith A, et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals
does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther
2018;47:516-25.
32. Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting
antiviral treatment: a prospective cohort study. Lancet 2019;393:1453-64.
33. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on
mortality in patients with advanced liver disease. Hepatology 2019;69:487-97.
34. Buonomo AR, Scotto R, Coppola C, Pinchera B, Viceconte G, et al. Direct acting antivirals treatment for hepatitis C virus infection
does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort).
Medicine (Baltimore) 2020;99:e18948.
35. Colussi G, Donnini D, Brizzi RF, Maier S, Valenti L, et al. Sustained virologic response to direct-acting antiviral agents predicts better
outcomes in hepatitis C virus-infected patients: a retrospective study. World J Gastroenterol 2019;25:6094-106.
36. Ebel F, Deterding K, Port K, Schlevogt B, Manns MP, et al. Letter: a 5-year long-term follow-up study after DAA treatment confirms a
reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. Aliment Pharmacol Ther 2020;51:194-5.
37. Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, et al. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting
antiviral agents. Hepatology 2020;71:44-55.
38. Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, et al. Direct-acting antiviral agents do not increase the incidence of hepatocellular
carcinoma development: a prospective, multicenter study. Hepatol Int 2019;13:293-301.
39. Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after
HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology 2019;157:1264-78.e4.